Guan et al. mechanistically demonstrated that the nelfinavir-mediated accumulation of SREBP-1 and ATF6 in prostate cancer cells were the outcome of inhibition of the enzyme S2P by the drug [65]. This evidence concerns the gene ATF6 and prostate carcinoma.